These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9559796)

  • 21. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
    Jacobs MR; Aronoff SC; Johenning S; Yamabe S
    J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
    Arias CA; Singh KV; Panesso D; Murray BE
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
    Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
    Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis.
    Markowitz SM; Wells VD; Williams DS; Stuart CG; Coudron PE; Wong ES
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1075-80. PubMed ID: 1929246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
    Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro response to bactericidal activity of cell wall-active antibiotics does not support the general opinion that enterococci are naturally tolerant to these antibiotics.
    Fontana R; Grossato A; Ligozzi M; Tonin EA
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1518-22. PubMed ID: 2171422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
    Credito KL; Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2027-31. PubMed ID: 10428930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G
    Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Enterococcus faecalis clinical isolates with 'penicillin-resistant, ampicillin-susceptible' phenotype as reported by Vitek-2 Compact system.
    Tan YE; Ng LS; Tan TY
    Pathology; 2014 Oct; 46(6):544-50. PubMed ID: 25158809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-kill kinetic studies of ampicillin/sulbactam for beta-lactamase-producing enterococci.
    Patterson JE; Farrel P; Zervos MJ
    Diagn Microbiol Infect Dis; 1991; 14(6):495-9. PubMed ID: 1802536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory and bactericidal effects of telithromycin (HMR 3647, RU 56647) and five comparative antibiotics, used singly and in combination, against vancomycin-resistant and vancomycin-susceptible enterococci.
    Baltch AL; Smith RP; Ritz WJ; Bopp LH
    Chemotherapy; 2001; 47(4):250-60. PubMed ID: 11399861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.
    Credito KL; Lin G; Pankuch GA; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):67-72. PubMed ID: 11120946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.